@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech
@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce
@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- $ZAFG CEO on going public. More | Follow @DamianFierce
@EmilyMFierce: You know you're reading a press release from the U.K. when it has the word "whilst" in it. | Follow @EmilyMFierce
> Deerfield has acquired the last $40 million batch of senior debt notes from MannKind ($MNKD). This is the final tranche in their $160 million debt deal sealed last year. SEC
> Phosphagenics, an Australian drug delivery company, says it has raised A$12.2 million of its A$16.3 million capital raising program. Release
> Vernalis and Tris Pharma say they achieved of proof-of-concept for CCP-08, the third program to achieve this milestone in their U.S. prescription cough cold collaboration. Release
Medical Device News
@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev
@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence
@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2
@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce
@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce
> Intersect, Ocular ready to test the med tech IPO waters. Article
> Smart bandage advances patient monitoring technology. More
> Spinal fusion implants enter market amid growing skepticism from insurers. Article
Pharma News
@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma
@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton
@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce
@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce
> News flash for biopharma bosses: More than half your employees want to leave. Story
> Cost-conscious payers are eyeing higher prices on diabetes drugs. Report
> Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data. Article
> Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter. More
Biotech Research News
> Top 15 NIH-funded disease areas. Report
> Simulated human heart aims to screen drugs for adverse effects. More
> First U.S.-acquired chikungunya case detected. Item
> Simulated human heart aims to screen drugs for adverse effects. Article
> Enzyme may provide new target for Alzheimer's disease. Story
Pharma Manufacturing News
> FedEx to fight charges it was key link in supply chain for illegal drugs. News
> FDA again warns that Texas compounder's products may not be sterile. Item
> GSK, J&J push for genetic engineering of opium. More
> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story
> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article